Brief: Gubra Says Neuropeptide Agonist Shows No Unexpected Safety Concerns

Gubra A/S

17/05/2023 06:59

May 17 (Reuters) - Gubra A/S  GUBRA.CO :
    * BI 1820237 A NOVEL LONG-ACTING NEUROPEPTIDE Y RECEPTOR
TYPE 2
(NPY2) AGONIST, HAS BEEN EVALUATED IN A PHASE 1 CLINICAL TRIAL
    * TRIAL SHOWED NO UNEXPECTED SAFETY CONCERNS, AND POSITIVE
EFFECTS
ON ENERGY INTAKE AND GASTRIC EMPTYING

Source text for Eikon:  ID:nMFNZ3yl4 
Further company coverage:  GUBRA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))